Ingalls Kerry D. 4
4 · Poseida Therapeutics, Inc. · Filed Mar 18, 2022
Insider Transaction Report
Form 4
Ingalls Kerry D.
Chief Operating Officer
Transactions
- Purchase
Common Stock
2022-03-16$3.98/sh+3,000$11,940→ 55,000 total
Footnotes (1)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.965 to $3.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.